1-8 of 8
Samuel Ng
Close
Sort by
Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Christine E. Ryan, Benjamin L. Lampson, Svitlana Tyekucheva, Liam R. Hackett, Yue Ren, Samantha J. Shupe, Stacey M. Fernandes, Jennifer L. Crombie, Samuel Ng, Austin I. Kim, Inhye E. Ahn, Matthew J Weinstock, Samantha Pazienza, Josie S. Montegaard, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Jon E. Arnason, Steve Lo, Adam Olszewski, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2022) 140 (Supplement 1): 837–838.
https://doi.org/10.1182/blood-2022-168003
Published: 2022
Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Reid W Merryman, Robert A. Redd, Arnold S. Freedman, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D Jacobsen, Austin I. Kim, Ann S. LaCasce, Samuel Ng, Oreofe O. Odejide, Erin Michelle Parry, Iris Isufi, Justin Kline, Jonathon B. Cohen, Neha Mehta-Shah, Nancy L. Bartlett, Matthew Mei, Philippe Armand, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6531–6533.
https://doi.org/10.1182/blood-2022-159823
Published: 2022
Journal Articles

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Ann S. LaCasce, David C. Fisher, Alex F. Herrera, Caron A. Jacobson, Austin I. Kim, Reid W Merryman, Oreofe O. Odejide, Samuel Ng, Yago Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine Zain, Philippe Armand, Eric D Jacobsen
Journal: Blood
Blood (2022) 140 (Supplement 1): 1185–1187.
https://doi.org/10.1182/blood-2022-164839
Published: 2022
Journal Articles

TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Tayla B. Heavican-Foral, Huiyun Liu, Geoffrey M. Nelson, Lu Yang, Renee Chen, Marcus Kenneth Jones, Ran Xu, Ajit Johnson Nirmal, Salvia Jain, Catharine Leahy, Kristen Lynn Jones, Kristen E. Stevenson, Wenchao Wu, Abner Louissaint, Jr., Lydie Debaize, Wing C. Chan, Shannan Ho Sui, Samuel Ng, Andrew L. Feldman, Matthew Meyerson, Karen Adelman, chun-Wei David Chen, Myles Brown, David M. Weinstock
Journal: Blood
Blood (2022) 140 (Supplement 1): 1696–1697.
https://doi.org/10.1182/blood-2022-163368
Published: 2022
Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, Stephen J. F. Chong, Mary C. Collins, Rebecca Valentin, Liam Hackett, Olivier Tournilhac, François Lemonnier, Jehan Dupuis, Adrien Daniel, Cecile Tomowiak, Kamel Laribi, Loïc Renaud, Damien Roos-Weil, Cedric Rossi, Eric Van Den Neste, Cecile Leyronnas, Fatiha Merabet, Jean Valère Malfuson, Mourad Tiab, Loïc Ysebaert, Samuel Ng, Franck Morschhauser, Philipp B. Staber, Matthew S. Davids
Journal: Blood
Blood (2021) 137 (25): 3495–3506.
https://doi.org/10.1182/blood.2020007303
Published: 2021
Includes: Supplemental data
Journal Articles

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Matthew S. Davids, MD, Benjamin L. Lampson, MD PhD, Svitlana Tyekucheva, PhD, Jennifer L. Crombie, MD, Samuel Ng, MD PhD, Austin I. Kim, MD, Matthew Weinstock, MD, Jessica Lowney, Samantha Pazienza, Josie Montegaard, NP, Victoria Patterson, BSN, RN, Caron A. Jacobson, MD, Ann S. LaCasce, MD MSc, Philippe Armand, MD PhD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-139864
Published: 2020
Journal Articles

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Reid W Merryman, MD, Robert A. Redd, MS, Eleanor Taranto, MD, Gulrayz Ahmed, MD, Erin Jeter, Kristin M McHugh, Jennifer R. Brown, MD PhD, Jennifer Crombie, MD, Matthew S. Davids, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Eric Jacobsen, MD, Caron Jacobson, MD MMSc, Austin I. Kim, MD, Ann S. LaCasce, MD MSc, Benjamin L. Lampson, MD PhD, Samuel Ng, MD PhD, Oreofe O. Odejide, MDMPH, Parastoo B. Dahi, MD, Yago Nieto, MD, Robin M. Joyce, MD, Yi-Bin Chen, MD, Alex F. Herrera, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-140965
Published: 2020
Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Charles Herbaux, MD MSc, Christoph Kornauth, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Mary C Collins, BA, Rebecca Valentin, MD, Stephen Jun Fei Chong, PhD, Jehan Dupuis, MD, Adrien Daniel, Micha Srour, MD, Cecile Tomowiak, MD, Kamel Laribi, MD, Damien Roos-Weil, Cedric Rossi, MD PhD, Nicolas Vanlangendonck, MSc, Cecile Leyronnas, Fatiha Merabet, MD, Jean Valère Malfuson, MD, Mourad Tiab, Samuel Ng, MD PhD, Franck Morschhauser, MD, Philipp Bernhard Staber, MD PhD, Matthew S. Davids, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 807.
https://doi.org/10.1182/blood-2019-126773
Published: 2019